Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) skin and soft tissue infections (SSTIs), such as impetigo, cellulitis, folliculitis, and infected wounds and ulcers, have been increasing for more than a decade and are creating a serious public health concern (1, 2). In particular, outpatient and emergency room visits for SSTIs have been estimated to result in 11.6 to 14.2 million ambulatory care visits per year in the United States (3, 4). In 2004 and 2008, CA-MRSA was identified as the most common cause (59%) of all SSTIs presenting to emergency rooms across the United States (5, 6). In these and other studies, the USA300 clone has been isolated in up to 90% of all CA-MRSA SSTIs in the United States (5–8). USA300 causes severe and necrotic SSTIs and often causes infections in otherwise healthy individuals without any known risk factors for infection (1, 2, 9).

Uncomplicated CA-MRSA SSTIs, such as impetigo, infected abrasions, and folliculitis/furunculosis can be managed in an outpatient setting with oral antibiotics and/or incision and drainage (10–12). Typical oral antibiotic regimens used for CA-MRSA SSTIs include a tape-stripping model (17, 18), a burned skin model (19–21), and a skin surgical/suture wound (22–25). However, in these models, large numbers of animals are required because animals need to be euthanized at various time points after infection to evaluate the *ex vivo* efficacy of systemic and topical antimicrobial agents. A preclinical animal model system is an important step to evaluate the efficacy of an antimicrobial agent before more extensive studies are performed in human subjects. Previous animal models to evaluate *S. aureus* MRSA SSTIs include a tape-stripping model (17, 18), a burned skin model (19–21), and a skin surgical/suture wound (22–25). However, in these models, large numbers of animals are required because animals need to be euthanized at various time points after infection to evaluate the *ex vivo* bacterial burden by performing traditional CFU counting. The aim of the present study was to develop a mouse model of CA-MRSA wound infection, which utilizes *in vivo* bioluminescence imaging to monitor the bacterial burden, represents an alternative method to evaluate the preclinical *in vivo* efficacy of systemic and topical antimicrobial agents.

*In Vivo* Bioluminescence Imaging To Evaluate Systemic and Topical Antibiotics against Community-Acquired Methicillin-Resistant *Staphylococcus aureus*-Infected Skin Wounds in Mice

Yi Guo, Romela Irene Ramos, John S. Cho, Niles P. Donegan, Ambrose L. Cheung, Lloyd S. Miller

Department of Medicine, Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USA; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA; Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) frequently causes skin and soft tissue infections, including impetigo, cellulitis, folliculitis, and infected wounds and ulcers. Uncomplicated CA-MRSA skin infections are typically managed in an outpatient setting with oral and topical antibiotics and/or incision and drainage, whereas complicated skin infections often require hospitalization, intravenous antibiotics, and sometimes surgery. The aim of this study was to develop a mouse model of CA-MRSA wound infection to compare the efficacy of commonly used systemic and topical antibiotics. A bioluminescent USA300 CA-MRSA strain was inoculated into full-thickness scalpel wounds on the backs of mice and digital photography/image analysis and *in vivo* bioluminescence imaging were used to measure wound healing and the bacterial burden. Subcutaneous vancomycin, daptomycin, and linezolid similarly reduced the lesion sizes and bacterial burden. Oral linezolid, clindamycin, and doxycycline all decreased the lesion sizes and bacterial burden. Oral trimethoprim-sulfamethoxazole decreased the bacterial burden but did not decrease the lesion size. Topical mupirocin and retapamulin ointments both reduced the bacterial burden. However, the petrolatum vehicle ointment for retapamulin, but not the polyethylene glycol vehicle ointment for mupirocin, promoted wound healing and initially increased the bacterial burden. Finally, in type 2 diabetic mice, subcutaneous linezolid and daptomycin had the most rapid therapeutic effect compared with vancomycin. Taken together, this mouse model of CA-MRSA wound infection, which utilizes *in vivo* bioluminescence imaging to monitor the bacterial burden, represents an alternative method to evaluate the preclinical *in vivo* efficacy of systemic and topical antimicrobial agents.
infection using a newly generated USA300 strain that possesses a stable bioluminescent construct to compare the efficacy of commonly used systemic and topical antibiotics.

**MATERIALS AND METHODS**

**CA-MRSA bioluminescent strain.** The USA300 LAC::lux bioluminescent CA-MRSA strain, derived from the USA300 LAC parent strain, was used in all experiments (26). USA300 LAC::lux possesses a modified luxABCDE operon from the bacterial insect pathogen *Photobacterium luminescens*, which was chromosomally transduced from the Xen29 bioluminescent S. aureus strain (Caliper, Perkin-Elmer Company, Alameda, CA) (27). This resulted in a bioluminescent USA300 LAC::lux strain that constitutively emits a blue-green light with a maximal emission wavelength of 490 nm (only live and metabolically active bacteria will emit light). The bioluminescent construct is stably integrated into the bacterial chromosome and is maintained in all progeny without selection.

**Preparation of bacteria for inoculation.** USA300 LAC::lux bacteria were streaked onto tryptic soy agar plates (tryptic soy broth [TSB] plus 1.5% Bacto agar [BD Biosciences, Franklin Lakes, NJ]) and grown at 37°C overnight (28). Single bacterial colonies were cultured in TSB and grown overnight at 37°C in a shaking incubator (MaxQ 4450; Thermo Fisher Scientific, Waltham, MA). Mid-logarithmic-phase bacteria were obtained after a 2-h subculture of a 1/50 dilution of the overnight culture. Bacteria were pelleted, resuspended, and washed three times in phosphate-buffered saline (PBS). Bacterial inocula (2 × 10^5 CFU, 2 × 10^6 CFU, or 2 × 10^7 CFU in 10 µl of PBS) were estimated by measuring the absorbance at 600 nm (Biomate 3; Thermo Fisher Scientific). CFU were verified after an overnight culture.

**Mice.** Six-week-old male C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME). In some experiments, 12-week-old NONCnZO10/LtJ male mice (Jackson Laboratories) on a 10 to 11% (wt/wt) chow diet (LabDiet 5k20; PMI Nutrition International, St. Louis, MO) were used (29). NONCnZO10/LtJ male mice by 10 weeks of age develop a disease closely mimicking human type 2 diabetes with visceral obesity, hyperglycemia, dyslipidemia, moderate liver steatosis, and pancreatic islet atrophy (29) and were confirmed to have hyperglycemia (blood glucose levels > 300 mg/dl) before they were used in experiments. Mice were housed in one mouse per cage and in specific-pathogen-free conditions.

**Mouse model of CA-MRSA skin wound infection using in vivo bioluminescence imaging.** All procedures were approved by the UCLA Animal Research Committee. Mice were anesthetized with inhalation isoflurane (2%), the posterior upper backs were shaved and three parallel 8-mm linear full-thickness scalp cuts (#11 blade) were made through the dermis (28). The wounds were subsequently inoculated with USA300 LAC::lux (2 × 10^5 CFU, 2 × 10^6 CFU, or 2 × 10^7 CFU in 10 µl of PBS) using a micropipette. To obtain measurements of wound sizes, mice were anesthetized with inhalation isoflurane (2%) at several different time points after infection (e.g., days 0, 1, 3, 5, 7, and 10) and digital photographs of the infected-skin wounds were taken. The total lesion size (cm²) was quantified by using the image analysis software program ImageJ (NIH Research Services Branch [http://rsweb.nih.gov/ij/]) and a millimeter ruler as a reference. A measurement of bacterial burden was obtained by performing *in vivo* bioluminescence imaging at the same time points using the Lumina II imaging system (Caliper). *In vivo* bioluminescence imaging data are presented on a color-scale overlaid on a grayscale photograph of mice and quantified as total flux (photons/s) within a circular region of interest using Living Image software (Caliper). In some experiments, to confirm that the *in vivo* bioluminescent signals accurately represented the bacterial burden, *in vivo* CFU counts were determined after overnight cultures of homogenized (Pro200 Series homogenizer; Pro Scientific, Oxford, CT) 8-mm punch biopsy specimens of lesional skin taken at 4 h and on days 1, 3, 5, and 7 after inoculation. Typically, 5 to 10 mice per group were used, and the numbers of mice used in each experiment are indicated in the figure legends.

**Subcutaneous and oral antibiotic therapy.** Based on previously published studies, mice were administered subcutaneous (to the flank skin) or oral (via gavage) therapeutic doses of vancomycin (110 mg/kg administered subcutaneously twice daily) (30, 31) (Novaplus; Hospira, Inc., Lake Forest, IL), doxycyclin (50 mg/kg administered subcutaneously daily) (32, 33) (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA), lincomed (60 mg/kg administered subcutaneously and orally twice daily) (34) (Zyvox; Pfizer, Inc., New York, NY), clindamycin (100 mg/kg administered orally three times a day) (35, 36) (Cloxicin phosphate; Pfizer, Inc.), doxycycline (100 mg/kg orally twice daily) (33), and TMP-SMX (320/1,600 mg/kg administered orally twice daily) (37, 38). Linezolid was used at the same dose for subcutaneous and oral administration because of equivalent bioavailability when given via either route (39). These doses were chosen to approximate the free-drug area under the curve (AUC) of typical human doses of intravenous vancomycin (440 µg·h/ml for 1 g twice daily) (40), intravenous daptomycin (598 µg·h/ml for 6 mg/kg daily) (41), intravenous/oral linezolid (138 µg·h/ml for 600 mg/kg twice daily) (42), clindamycin (116 µg·h/ml for 600 mg three times a day) (33), and doxycycline (55.7 µg·h/ml for 100 mg twice daily) (43). All mice were treated with the first dose of antibiotics administered at 4 h after CA-MRSA inoculation and continued at the aforementioned regimens for 7 days. For the USA300 LAC::lux strain, the following MICs were measured according to established guidelines and methods (44) using in-house prepared broth microdilution trays: oxacillin, 16 µg/ml; vancomycin, 1.0 µg/ml; daptomycin, ≤0.25 µg/ml; linezolid, 2.0 µg/ml; clindamycin, ≤0.5 µg/ml; doxycycline, ≤1.0 µg/ml; and TMP/SMX, ≤0.5/≤9.5 µg/ml.

**Topical antibiotic therapy.** CA-MRSA-infected skin wounds were treated topically by applying 100 µl of mupirocin 2% ointment (Bactroban; GlaxoSmithKline, Research Triangle Park, NC), retapamulin 1% ointment (Altabax; Stiefel/GlaxoSmithKline), or the corresponding vehicle ointments (polyethylene glycol [mupirocin] and white petrolatum [retapamulin]) at 4 h after CA-MRSA inoculation, followed by twice daily (every 12 h) thereafter for a total of 7 days.

**Statistical analysis.** Data were compared using Student’s t test (two-tailed). All data are expressed as mean ± the standard error of the mean (SEM). Values of *P* < 0.05 were considered statistically significant.

**RESULTS**

**In vivo bioluminescence imaging to measure bacterial burden.** To model a CA-MRSA wound infection in mice, scalp cuts on the shaved backs of mice were inoculated with the bioluminescent USA300 LAC::lux strain (26). The wound lesion sizes (Fig. 1A and B) and *in vivo* bacterial burden (Fig. 1C and D) of anesthetized mice were determined by analyzing digital photographs of the mice using image analysis (ImageJ; NIH Research Services Branch) and measuring the USA300 LAC::lux bioluminescent signals (Lumina II imaging system; Caliper), respectively. As a first step, the optimal bacterial inoculum that produced a consistent wound infection was determined by evaluating different inocula of USA300 LAC::lux (2 × 10^5, 2 × 10^6, and 2 × 10^7 CFU per 10 µl) or no bacterial inoculation (none) (Fig. 1). The inoculum of 2 × 10^7 CFU induced the largest lesions and the 2 × 10^6 CFU induced intermediate lesion sizes, which were both statistically greater than those of uninfected mice (Fig. 1A and B). In contrast, 2 × 10^5 CFU induced lesions that did not significantly differ from uninfected mice. The inoculum of 2 × 10^6 CFU produced a consistent wound infection was determined by evaluating different inocula of USA300 LAC::lux (2 × 10^5, 2 × 10^6, and 2 × 10^7 CFU per 10 µl) or no bacterial inoculation (none) (Fig. 1). The inoculum of 2 × 10^7 CFU induced the largest lesions and the 2 × 10^6 CFU induced intermediate lesion sizes, which were both statistically greater than those of uninfected mice (Fig. 1A and B). In contrast, 2 × 10^5 CFU induced lesions that did not significantly differ from uninfected mice.
background bioluminescent signals of uninfected mice. Since our ultimate goal was to produce a CA-MRSA wound infection that induced relatively small lesion sizes and bioluminescent signals that were greater than the uninfected wounds, the intermediate inoculum of $2 \times 10^6$ CFU was used in all subsequent experiments.

**Correlation of in vivo bioluminescent signals with ex vivo bacterial burden.** To evaluate whether bioluminescent signals of USA300 LAC::lux accurately represented the bacterial burden, *in vivo* bioluminescence imaging and skin biopsies from the infected wounds were performed on the same mice after inoculation with $2 \times 10^5$ CFU of USA300 LAC::lux. At 4 h and on days 1, 3, 5, and 7 after inoculation, the bioluminescent signals were $9.56 \pm 1.55 \times 10^5$, $1.72 \pm 0.07 \times 10^5$, $1.05 \pm 0.17 \times 10^5$, $5.0 \pm 0.37 \times 10^4$, and $2.84 \pm 0.18 \times 10^4$ photons/s (see Fig. S1A in the supplemental material) and the *ex vivo* bacterial burden was $1.29 \pm 0.21 \times 10^7$, $2.95 \pm 0.34 \times 10^6$, $2.29 \pm 0.40 \times 10^6$, $2.7 \pm 0.42 \times 10^5$, and $2.97 \pm 0.78 \times 10^4$ CFU (see Fig. S1B in the supplemental material), respectively. These *in vivo* bioluminescent signals highly correlated with the *ex vivo* CFU values (correlation coefficient $R^2 = 0.9996$) (Fig. 2). These data indicate that *in vivo* bioluminescence imaging of wounds infected with USA300 LAC::lux provides an accurate measurement of the *in vivo* bacterial burden that can be measured noninvasively and longitudinally during the course of an infection. It should be noted that the culture plates used to

**FIG 1** Mouse model of CA-MRSA wound infection. Three 8 mm in length, parallel, full-thickness scalpel wounds on the backs of C57BL/6 mice were inoculated with $2 \times 10^5$, $2 \times 10^6$, or $2 \times 10^7$ CFU of the bioluminescent CA-MRSA strain, USA300 LAC::lux, or no bacteria (none)/$10^5$ ($n = 5$ mice per group). (A) Mean total lesion size (cm$^2$) \pm the standard error of the mean (SEM). (B) Representative photographs of the lesions of the entire dorsal back (upper panels) and close-up photographs of the lesions (lower panels) are shown. (C) Bacterial counts as measured by *in vivo* bioluminescence imaging (mean total flux [photons/s] \pm the SEM) (logarithmic scale). (D) Representative *in vivo* bioluminescent signals on a color scale overlaid on top of a grayscale image of mice. *, $P < 0.05$; †, $P < 0.01$; ‡, $P < 0.001$ (USA300 LAC::lux-infected mice versus none) (Student’s $t$ test [two-tailed]).
between the various antibiotic treatment groups. Taken together, these data indicate that subcutaneously administered therapeutic doses of vancomycin, daptomycin, and linezolid all resulted in similar decreased lesion sizes and bioluminescent signals during a CA-MRSA wound infection in mice.

To compare the efficacy of commonly used oral antibiotics that are used for outpatient therapy of CA-MRSA SSTIs (12), clindamycin (100 mg/kg three times a day) (35, 36), linezolid (60 mg/kg twice daily) (34), doxycycline (100 mg/kg twice daily) (33), TMP-SMX (320/1,600 mg/kg twice daily) (37, 38), or sterile saline (sham control) were administered orally beginning at 4 h after USA300 LAC::lux inoculation and continued as indicated through day 7. Mice treated with oral linezolid had significantly decreased lesion sizes compared with sham control mice beginning on day 3, whereas mice treated with clindamycin or doxycycline had significantly decreased lesion sizes beginning on day 5 (Fig. 3C and E). TMP/SMX was the only oral antibiotic evaluated that did not result in significantly decreased lesion sizes compared with sham control mice (Fig. 3E). Oral linezolid had the most rapid therapeutic effect because it resulted in the most substantial decrease in bioluminescent signals (8.3-fold on day 1), which was significantly lower compared with the decreased bioluminescent signals in mice treated with oral clindamycin (2.7-fold on day 1) (P < 0.05) (Fig. 3D). Oral TMP/SMX and doxycycline had bioluminescent signals that were decreased compared with sham control mice beginning on day 3 after inoculation (3.0- and 2.6-fold on day 3, respectively) (P < 0.05) (Fig. 3F). After day 3, all of the oral antibiotics resulted in bioluminescent signals that approached background levels by days 5 to 7. In summary, these data indicate that oral linezolid, clindamycin, and doxycycline, but not TMP/SMX, resulted in decreased lesion sizes. In addition, all of these oral antibiotics resulted in decreased bioluminescent signals with linezolid having the most rapid therapeutic effect.

**Efficacy of topical antibiotic therapy.** Next, the efficacy of the two Food and Drug Administration (FDA)-approved topical prescription-strength ointments, mupirocin (1, 10, 11) and retapamulin (1, 10, 16), were compared in this mouse model of CA-MRSA wound infection. Mupirocin 2% ointment, retapamulin 1% ointment, or corresponding vehicle ointments (polyethylene glycol [PEG; mupirocin] and white petrolatum [retapamulin]) were topically applied (100-μl volume) to the infected wounds at 4 h after USA300 LAC::lux inoculation followed by twice daily (every 12 h) for the next 7 days. Mupirocin ointment resulted in 29 to 58% decreased lesion sizes beginning at day 5 after inoculation compared with the PEG vehicle ointment (Fig. 4B). In contrast, retapamulin ointment resulted in lesion sizes that did not differ from mice treated with petrolatum vehicle ointment alone. Compared with their respective vehicle ointments, between days 1 and 5, mupirocin ointment resulted in a 5- to 12-fold significant reduction in bioluminescent signals, whereas retapamulin ointment treatment resulted in a 10- to 41-fold significant reduction in bioluminescent signals (Fig. 4B). However, when the lesion sizes and bioluminescent signals for the mupirocin and retapamulin ointments were compared, they were not significantly different from each other. Interestingly, the observed differences in effectiveness of these ointments were impacted by changes induced by the vehicle ointment alone. In particular, the petrolatum vehicle ointment induced decreased lesion sizes that were comparable to those of mice treated with mupirocin or retapamulin ointment. This enhanced wound healing was unexpected because the petrol-
latum vehicle ointment also induced an increase in bioluminescent signals on day 1. In contrast, the PEG vehicle ointment had lesion sizes or bioluminescent signals that were similar to those observed without any topical treatment (saline control mice) in Fig. 3.

Efficacy of systemic antibiotics in a mouse model of type 2 diabetes. One advantage of developing a mouse model of CA-MRSA wound infection is that the efficacy of antibiotic therapy can be evaluated in genetically engineered mouse strains that mimic certain human diseases. One such disease is type II diabetes in which patients develop chronic wounds and ulcers that can become infected with CA-MRSA (46). To determine the efficacy of antibiotic therapy against a CA-MRSA wound infection in a mouse model of type II diabetes, the NONcNZO10/LtJ mouse strain, which expresses six known obesity-induced diabetes quantitative trait loci, was used (29). NONcNZO10/LtJ male mice on a high-fat diet develop many of the characteristics of type II diabetes when they become 10 weeks of age, including visceral obesity, hyperglycemia, dyslipidemia, moderate liver steatosis, and pancreatic islet atrophy (29). Vancomycin (110 mg/kg twice daily) (30, 31), daptomycin (50 mg/kg daily) (32, 33), linezolid (60 mg/kg twice daily) (34), or sterile saline (sham control) were administered subcutaneously to 12-week-old NONcNZO10/LtJ diabetic male mice beginning at 4-h after USA300 LAC::lux inoculation and continued at the above regimens through day 7. Although pharmacokinetic studies with vancomycin, daptomy-
cin, and linezolid were not performed on these diabetic mice, these doses used were based on total body weight, which is how vancomycin and daptomycin are dosed in humans and levels of linezolid at normal dosing are decreased in obese patients (12, 47).

As expected, sham control NONcNZO10/LtJ mice developed larger lesions and higher in vivo bioluminescent signals that persisted longer (up to 14 days) compared with wild-type C57BL/6 mice used in Fig. 3 (Fig. 5). In NONcNZO10/LtJ mice, subcutaneously administered vancomycin resulted in significantly decreased lesion sizes on day 7 (22% decrease \[
p < 0.05\]
), and subcutaneously administered daptomycin and linezolid resulted in significantly decreased lesion sizes on day 5 (19% \[
p < 0.05\]
 and 23% \[
p < 0.05\]
 decreases, respectively) and day 7 (38% \[
p < 0.01\]
 and 44% \[
p < 0.001\]
 decreases, respectively) compared with sham control mice (Fig. 5A). On day 1, vancomycin-, daptomycin-, and linezolid-treated mice had similarly decreased bioluminescent signals compared with sham control mice. Taken together, in NONcNZO10/LtJ diabetic mice, subcutaneous linezolid and daptomycin treatment had a more rapid therapeutic effect compared with vancomycin, but after day 1, all three antibiotics had similar efficacy against this CA-MRSA wound infection.

**DISCUSSION**

CA-MRSA SSTIs represent a major public health threat in the United States and are becoming an increasing problem worldwide (1, 2, 13). Antimicrobial resistance among CA-MRSA isolates has complicated the treatment of these infections. A rapid and cost-effective preclinical animal model of CA-MRSA SSTIs could provide an alternative system to evaluate the in vivo efficacy of existing and potential antimicrobial agents. In the present study, a mouse model of a CA-MRSA skin wound infection was developed in

![Image](http://aac.asm.org/)  
**FIG 4** Efficacy of topical antibiotics against CA-MRSA-infected wounds. Scalpel wounds on the backs of mice were inoculated with USA300 LAC::lux \((2 \times 10^6 \text{ CFU/10}^3 \mu \text{l})\). Mice (\(n = 5\) mice per group) were treated with topical mupirocin 2% ointment, retapamulin 1% ointment, or the corresponding vehicle ointment (polyethylene glycol [mupirocin] and white petrolatum [retapamulin]). Antibiotic treatment was initiated at 4 h after CA-MRSA inoculation and continued twice daily for the first 7 days. (A) Mean total lesion size (\(\text{cm}^2\)) \(\pm\) the SEM. (B) Bacterial counts as measured by in vivo bioluminescence imaging (mean total flux [photons/s] \(\pm\) the SEM) (logarithmic scale). \(*, p < 0.05; †, p < 0.01; ‡, p < 0.001\) (antibiotic treatment versus sham treatment [saline]) (Student’s \(t\) test [two-tailed]).

![Image](http://aac.asm.org/)  
**FIG 5** Efficacy of subcutaneous vancomycin, daptomycin, and linezolid against a CA-MRSA wound infection in diabetic mice. Scalpel wounds on the backs of NONcNZO10/LtJ diabetic mice were inoculated with USA300 LAC::lux \((2 \times 10^6 \text{ CFU/10}^3 \mu \text{l})\). Mice (\(n = 5\) to 10 mice per group) were treated with subcutaneous vancomycin (110 mg/kg twice daily), daptomycin (50 mg/kg once daily), linezolid (60 mg/kg twice daily), or sterile saline (sham control) beginning at 4 h after CA-MRSA inoculation and continued for the first 7 days. (A) Mean total lesion size (\(\text{cm}^2\)) \(\pm\) the SEM. (B) Bacterial counts as measured by in vivo bioluminescence imaging (mean total flux [photons/s] \(\pm\) the SEM) (logarithmic scale). \(*, p < 0.05; †, p < 0.01; ‡, p < 0.001\) (antibiotic treatment versus sham treatment [saline]) (Student’s \(t\) test [two-tailed]).
which a bioluminescent USA300 CA-MRSA strain (USA300 LAC::lux) was inoculated into skin wounds. Digital photography and \textit{in vivo} bioluminescence imaging were used to obtain noninvasive and longitudinal measurements of wound healing and the bacterial burden.

The bioluminescent USA300 LAC::lux strain used in the present study has certain advantages compared with other available \textit{S. aureus} and CA-MRSA bioluminescent strains. First, this strain was derived from the clinical USA300 LAC strain, which produces toxins associated with the increased virulence of CA-MRSA, including phenol soluble modulins, alpha-toxin, and Panton-Valentine leukocidin (48, 49). USA300 LAC::lux also possesses the bioluminescent construct stably integrated into the bacterial chromosome (26). Since the bioluminescent construct is maintained in all progeny without selection, it is thus not lost \textit{in vivo} over time (26). We demonstrated that the \textit{in vivo} bioluminescent signals of USA300 LAC::lux highly correlated with the numbers of \textit{ex vivo} CFU harvested from the same infected skin wounds at various different time points (correlation coefficient \( R^2 = 0.9996 \)) (Fig. 2). Thus, \textit{in vivo} USA300 LAC::lux bioluminescent signals provide an accurate measurement of bacterial burden that does not require euthanasia of animals for traditional CFU counting to determine the bacterial burden at each time point. For example, only 5 to 10 mice per group were used to monitor the bacterial burden with \textit{in vivo} bioluminescence imaging. In contrast, to obtain CFU data from the infected skin, at least 5 mice per group would need to be euthanized at each time point (i.e., days 1, 3, 5, and 7), corresponding to 20 total mice per group. For future studies that seek to utilize techniques of \textit{in vivo} bioluminescence imaging to monitor the bacteria burden in other animal models of infection, the bioluminescent construct containing the modified \textit{lux}ABCDE operon, which was chromosomally induced from Xen29 (Caliper, a Perkin-Elmer Company, Alameda, CA) (27), could be transduced into other \textit{S. aureus} and MRSA strains (50, 51). Although, the \textit{in vivo} bioluminescent signals correlate with bacterial burden, they are also dependent upon the transcription/translation of the bioluminescent construct as well as the metabolic activity of the bacteria (50, 51). However, we and others have demonstrated that \textit{in vivo} bioluminescence imaging can be used to monitor the bacterial burden in various \textit{in vivo} models of biofilm formation (26, 27, 52), demonstrating that this technology is sensitive enough to detect low levels of light produced by bacteria in biofilms.

This mouse model was used to compare the efficacy of commonly used systemic antibiotics against CA-MRSA SSTIs. We found that subcutaneous administration of therapeutic doses of vancomycin, daptomycin, or linezolid were all effective in treating the CA-MRSA infection in mice, suggesting that these antibiotics would have similar efficacy against CA-MRSA SSTIs in humans. In addition, both subcutaneous linezolid and daptomycin had a more rapid therapeutic effect in type II diabetic mice compared to vancomycin, suggesting that linezolid and daptomycin might have an additional clinical benefit in the context of diabetes. However, these preliminary results with these diabetic mice should be interpreted with caution since detailed pharmacokinetics studies were not performed on these mice, and the dosages used were based on total body weight. Nonetheless, there have been studies in humans that evaluated the efficacy of intravenous daptomycin or linezolid as single agents compared with intravenous vancomycin in the treatment of CA-MRSA SSTIs. In general, daptomycin has been shown to have increased efficacy compared with vancomycin (53). However, one study demonstrated that daptomycin had similar efficacy compared with vancomycin in the treatment of diabetic foot ulcers (54). Most studies have found that linezolid has equivalent or superior efficacy compared with vancomycin (55–60) and similar efficacy as vancomycin in diabetic patients (57). Given these findings in humans, this mouse model was able to confirm the efficacy of these antibiotics against a CA-MRSA wound infection, but it was not able to recapitulate the potentially increased efficacy of linezolid or daptomycin compared with vancomycin in nondiabetic mice. The reason for this may be due to different pharmacokinetics (i.e., absorption, distribution, metabolism, and elimination) between the species, which is a limitation of preclinical animal models. Despite this drawback, we believe that the ability to monitor wound healing and bacterial burden longitudinally over time provides valuable preclinical information about overall efficacy, which is necessary to establish before the commencement of more comprehensive studies in humans.

Our findings involving the comparison of orally administered antibiotics to treat the CA-MRSA wound infections in mice indicated that linezolid, clindamycin, doxycycline, and TMP/SMX were all effective in reducing the bacterial burden, but linezolid had a more rapid therapeutic effect. The reason that the linezolid resulted in a more dramatic decrease in bacterial burden than clindamycin at day 1 after infection is not clear. As mentioned above, this result could be due to different pharmacokinetics of these antibiotics in mice. Nonetheless, it should be mentioned that inducible clindamycin resistance is found in up to 8.4% of CA-MRSA strains, and this should be taken into account when treating patients (61). In this mouse model, TMP/SMX was effective at reducing the bioluminescent signals at a high dose (320/1,600 mg/kg twice daily). However, TMP/SMX was the only oral antibiotic evaluated that had no efficacy in decreasing the size of the lesions. It should be mentioned that TMP/SMX at a lower dose (160/800 mg twice daily) had no efficacy in decreasing the lesion size or bioluminescent signals (data not shown), even though this strain was highly sensitive to this drug (MIC \( \leq 0.5 \) \( \mu \)g/ml). The high dose of TMP/SMX that was required for efficacy in this mouse model may be due the increased content of thymidine in mouse sera and tissues, which interferes with the activity of TMP (62). Since infected human tissues may also have increased thymidine levels, some studies have used high doses of TMP/SMX in treating CA-MRSA SSTIs in humans (37, 38).

Since this model of CA-MRSA SSTI involved the infection of open skin wounds, it provided an opportunity to evaluate the efficacy of topically applied antimicrobial agents. We compared two FDA-approved prescription-strength topical ointments, mupirocin 2% ointment and retapamulin 1% ointment. We found that both mupirocin and retapamulin ointments were equally effective in reducing the bacterial burden to levels seen with the subcutaneously and orally administered antibiotics. Interestingly, the white petrolatum ointment, the vehicle for retapamulin, initially induced an increase in the bacterial burden, which was not observed with PEG vehicle ointment for mupirocin. Despite this higher bacterial burden, the petrolatum ointment resulted in faster wound healing and the wound sizes were virtually identical to those treated with the mupirocin or retapamulin ointments. Therefore, the petrolatum vehicle ointment may provide a therapeutic benefit compared with the PEG vehicle ointment because it promoted wound healing. Clearly, the choice of
vehicle is an important consideration in the development of future topical antimicrobial therapies. It could be that a vehicle that enhances wound healing without affecting bacterial growth may be even more efficacious.

One limitation of our study is that we studied a single isolate of USA300 CA-MRSA and the virulence and antibiotic therapeutic effects may be different with other MRSA strains. Moreover, since we only evaluated the USA300 strain, we were not able to describe variability between strains, including differences between USA300 and USA100 strains, which are likely very different because USA100 strains produce fewer toxins and may be less virulent than USA300 strains. These limitations will require additional studies to resolve.

Taken together, the mouse model of CA-MRSA wound infection developed here utilized digital photography/image analysis and in vivo bioluminescence imaging to monitor wound healing and the bacterial burden longitudinally over time. Since this model does not require euthanasia to determine the bacterial burden, fewer numbers of animals are required to evaluate the efficacy of antimicrobial agents, which is an important consideration for the reduction, refinement, and replacement of animals used in research and testing. For this particular model, since the bioluminescent signals for the antibiotic treatment and the sham control groups were nearly identical by day 7, future experiments may not need to be extended beyond day 5, providing additional labor and experimental cost savings. This model could serve as an alternative or complementary noninvasive, cost-effective, and accurate preclinical animal model to investigate in vivo efficacy of certain systemic and topical antimicrobial agents before extensive studies in human subjects. Our results using this model indicate that there are several viable options for intravenous and oral antibiotic therapy for the treatment of CA-MRSA SSTIs in humans and topical antibiotic therapy may provide an additional therapeutic benefit.

ACKNOWLEDGMENTS

This study was supported by an Investigator-Initiated Research Grant from Pfizer, Inc. (grant W5751303 to L.S.M.), and National Institutes of Health grants R01-AI078910 (to L.S.M.), T32-AR058921 (to J.S.C.), and R24-CAG92865 (to the UCLA Small Animal Imaging Resource Program).

We thank Tammy Kielian, Kenneth W. Bayles, and Jennifer Endres at the University of Nebraska Medical Center for providing the USA300 LAC::lux bioluminescent CA-MRSA strain. We also thank Michael Lewinski and Kevin Ward at the UCLA Clinical Microbiology Laboratory for performing the antibiotic MICS for the bacterial strains used in this study.

REFERENCES


